Log In
BCIQ
Print this Print this
 

SAR245408, XL147

  Manage Alerts
Collapse Summary General Information
Company Exelixis Inc.
DescriptionOral selective inhibitor of phosphoinositide 3-kinase (PI3K)
Molecular Target Phosphoinositide 3-kinase (PI3K)
Mechanism of ActionPhosphoinositide 3-kinase (PI3K) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation
PartnerSanofi

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,161.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/01/2009

$1,161.0M

Undisclosed

Undisclosed

Get a free BioCentury trial today